-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Insmed, Raises Price Target to $230

Benzinga·12/16/2025 13:43:26
语音播报
Cantor Fitzgerald analyst Olivia Brayer maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $216 to $230.